Wearable heart monitor for AF screening increases diagnoses but not stroke prevention

Screening for atrial fibrillation (AF) using a wearable heart monitor for 2 weeks can identify older adults with this potentially dangerous abnormal heart rhythm, but does not prevent subsequent strokes, according to late breaking research presented in a Hot Line Session at this year’s ESC Congress 2024 in London, UK (30 Aug – 2 Sept).

StromaForte by Swedish StromaBio for Osteoarthritis: Likelihood of Approval – Pharmaceutical Technology

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

November 6, 2023

The Future of CBD research, marketing, and regulation

In this interview, Professor Ted Dinan, Medical Director at Atlantia Clinical Trials, and Asa Waldstein, Principal at Supplement Advisory Group, discuss Atlantia’s expertise in clinical

February 28, 2025

Trump’s pick of RFK Jr. at HHS: The scientific community, and biopharma investors, respond

Leaders throughout the biopharma world and scientific community struggled to process news on Thursday that President-elect Donald Trump has tapped Robert F. Kennedy Jr. to

November 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.